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INTRODUCTION
Spinal anesthesia provides a fast, profound, and symmetrical
sensory and motor block of high quality in patients undergo-
ing cesarean delivery (1, 2). The most common serious adverse
effect of spinal anesthesia for cesarean delivery is hypotension,
with a reported incidence greater than 80% (3).
A number of strategies for preventing hypotension have
been investigated, because it may have detrimental mater-
nal and neonatal effects. The use of lateral uterine displace-
ment is routine procedure to prevent hypotension (4). Other
strategies have included the use of intravenous fluid preload,
gravity (Trendelenburg or leg rising), compression devices on
the legs, and prophylactic vasopressors (1). However, no meth-
ods have proved satisfactory. Ephedrine is the most common-
ly used drug among the vasopressors.
The prophylactic administration of ephedrine by the intra-
muscular route is very controversial because its systemic ab-
sorption and peak effect are difficult to predict, thus, possi-
bly resulting in rebound hypertension (5). The intravenous
route may be more effective and controllable, although large
doses are used; the incidence of hypotension was still high in
some studies (6, 7).
Intravenous ephedrine given immediately after the induc-
tion of spinal anesthesia has been described (7, 8). Doses of
10-20-30 mg or 0.25 mg/kg were not effective in eliminat-
ing hypotension completely (7-10). Therefore, we designed
a randomized, double-blinded study to determine efficacy
and safety of 0.5 mg/kg intravenous ephedrine for preventing
hypotension during spinal anesthesia for cesarean delivery.
MATERIALS AND METHODS
During the study period, 52 consecutive patients were iden-
tified suitable for the study. They were women, ASA status
I or II, undergoing elective cesarean section under spinal anes-
thesia. Three had to be excluded because of hypertension, two
refused to participate, and one was missed because of high
workload. Written informed consent was obtained from each
subject, and the study protocol was approved by the Human
Ethics Committee of our medical school. Patients with pre-
existing or pregnancy-induced hypertension, known cardio-
vascular or cerebrovascular disease, abnormal cardiotocogra-
phy (CTG) tracing, or contraindications to spinal anesthesia
were excluded. Randomization was based on a computer-
generated code that was prepared at a remote site and sealed
in opaque, sequentially numbered envelopes. The patients
were randomly divided into 2 groups: ephedrine group (n=
23) and control group (n=23) after spinal anesthesia.
None of patients was premedicated. On arrival in the oper-
ation room, baseline measurements of systolic arterial pres-
sure (SAP) and heart rate (HR) were calculated with a Criti-
care System 1100 monitor (Criticare System Inc., Waukesha,
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The Effects of Intravenous Ephedrine During Spinal Anesthesia for
Cesarean Delivery: A Randomized Controlled Trial
We designed a randomized, double-blinded study to determine the efficacy and
safety of 0.5 mg/kg intravenous ephedrine for the prevention of hypotension during
spinal anesthesia for cesarean delivery. Patients were randomly allocated into two
groups: ephedrine group (n=21) and control group (n=21). Intravenous preload of
15 mL/kg lactated Ringer’s solution was given. Shortly after the spinal injection, ep-
hedrine 0.5 mg/kg or saline was injected intravenous for 60 sec. The mean of high-
est and lowest heart rate in the ephedrine group was higher than those of control
group (P<0.05). There were significant lower incidences of hypotension and nau-
sea and vomiting in the ephedrine group compared with the control group (8 [38.1%]
vs. 18 [85.7%]); (4 [19%] vs. 12 [57.1%], respectively) (P<0.05). The first rescue
ephedrine time in the ephedrine group was significantly longer (14.9±7.1 min vs.
7.9±5.4 min) than that of the control group (P<0.05). Neonatal outcome were simi-
lar between the study groups. These findings suggest, the prophylactic bolus dose
of 0.5 mg/kg intravenous ephedrine given at the time of intrathecal block after a crys-
talloid fluid preload, plus rescue boluses reduce the incidence of hypotension.
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1 min apart and in the modified supine position with at least
15 of left lateral tilt. 18-gauge intravenous cannula was sited
in the non-dominant hand and intravenous preload of 15 mL/
kg lactated Ringer’s solution was given, within 15 min, after
which the intravenous infusion was slowed to the minimum
rate required to maintain vein patency. 
Spinal anesthesia was administered with the patient in the
right lateral position. After skin infiltration with lidocaine,
a 25-gauge Whitacre needle was inserted at the L2-3 or L3-
4 vertebral interspace and hyperbaric 0.5% bupivacaine 2 mL
with fentanyl 10 μ g was injected intrathecally. The patient
was then immediately turned supine with left lateral tilt.
Oxygen 4 L/min was given by nasal cannula until delivery.
Shortly after the spinal injection, ephedrine 0.5 mg/kg in
the ephedrine group or saline in the control group was inject-
ed intravenous for 60 sec. All study medications were admin-
istered by an anesthetist not be involved in the care of the
patient or collection of data. A second anesthetist, blind to
identity of the study medication, managed the patient. The
study period started at the time of intrathecal injection and
ended when the umbilical cord was clamped. Systolic arte-
rial pressure and heart rate were recorded at 1-min intervals.
Fetal heart rate was monitored by using CTG continuously
until delivery. The baseline SAP and HR, lowest and highest
SAP and HR, nausea, vomiting, dizziness, and chest symp-
toms were recorded every minute. The first rescue ephedrine
time, total doses of rescue ephedrine, and total dose of used
ephedrine were also recorded. Upper sensory level of anes-
thesia was measured by assessing loss of pinprick discrimi-
nation at 10 min. All blocks extended to T5 or above, before
surgery was allowed to start.
Hypotension was defined as 20% decrease in SAP from
baseline. Hypertension was defined as 20% increase in SAP
from baseline. Maternal bradycardia was defined as heart rate
<60 beats/min and treated immediately by using intravenous
atropine 0.5 mg. Tachycardia was defined as heart rate >120
beats/min. Hypotension was treated immediately by using
rescue intravenous ephedrine 5 mg every minute until SAP
returned to normal values (>80% of baseline value).
After delivery, Apgar scores were assessed at 1 and 5 min
by the attending pediatrician. Arterial blood samples were
taken from umbilical cord for blood-gas analysis within 2
min. All patients received oxytocin 20 units/L in crystalloid
after delivery. 
Prospective power analysis showed that a sample size of
20 patients per study group would have 80% power at the
5% significance level to detect a difference of 50% in the
incidence of hypotension in the study group compared with
control, assuming a baseline incidence of 80%, as reported
in a published study of a similar patient group (10).
Data were presented as mean±standard deviation, medi-
an (range), or percentage, as appropriate. Statistical analyses
were performed Statistica 7.0. Software (Statsoft, Inc., Tulsa,
AR, U.S.A.). Demographic parameters, delivery time, first
rescue ephedrine time, umbilical arterial pH, SAP, and HR
were compared with t-test. Changes over time in SAP and
HR between and within the study groups, comparing values
at each time point, were analyzed with repeated measures
ANOVA followed by a post hoc Bonferroni test to identify
significant differences. Doses of total rescue and used ephe-
drine, Apgar scores, and upper sensory level were compared
with Mann-Withney U test. Hypotension, hypertension, tac-
hycardia, bradycardia and nausea and vomiting of the study
groups were compared with  2 or Fisher’s exact test, as appro-
priate. A Pvalue of <0.05 was considered significant.
RESULTS
Of 46 patients randomized, two in the both groups (n=21)
had to be excluded from data analysis because of the proto-
col violations. In each study group, 21 patients completed the
study protocol. There was no difference between the study
groups with regard to the age, weight, height, and delivery
time (P>0.05) (Table 1). All patients had adequate surgical
anesthesia. The median upper sensory level 10 min after the
intrathecal injection was T4 (T3-T5) for all the study groups.
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Values are mean±SD or median (min-max).
Ephedrine group Control group
(n=21) (n=21)
Age (yr) 25.6±4.1 27.9±6.3
Height (cm)  161.8±5.2 161.1±4.9
Weight (kg)  70.9±7.7 68.8±6.9
Upper sensory level (dermatome)  T4 (T3-T5) T4 (T3-T5)
Spinal to delivery time (min) 21.0±2.5 20.6±2.6
Table 1. Patient characteristics
Fig. 1. Baseline, the lowest, and highest systolic arterial pressure
(SAP) and heart rate (HR) of the study groups.
Values are mean±SD.
*P<0.05 vs. control group.
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*There was no significant difference in the SAP and HR vaues
at baseline between the study groups (P>0.05). The mean
highest and lowest HR in the ephedrine group was higher
than those of control group (P<0.05). There were significant
differences in mean lowest SAP between the study groups
(P<0.05). The mean highest SAP in the ephedrine group was
higher than that of control group, but this difference was not
significant (Fig. 1). From 2 to 8 min, the mean SAPs in the
control group were significantly lower than those of the ep-
hedrine group (P<0.05) (Fig. 2). From 6 to 12 min, signifi-
cant decreases of the mean SAP in the control group were ob-
served as compared with baseline (P<0.05) (Fig. 2). From 4
to 8 min, the mean HR in the control group was significant-
ly lower than those of the ephedrine group (P<0.05) (Fig. 3).
The incidences of hypotension, hypertension, tachycardia,
bradycardia, nausea or vomiting, the total doses rescue and
used ephedrine, and the first rescue ephedrine time are sum-
marized in Table 2. There was significant lower incidences
of hypotension in the ephedrine group compared with the con-
trol group (8 [38.1%] vs. 18 [85.7%]) (P<0.05). There were
significant lower incidences of nausea and vomiting in the
ephedrine group compared with the control group (4 [19%]
vs. 12 [57.1%]) (P<0.05). There was no difference in the ratio
of hypertension between the study groups (P>0.05). The ratio
of bradycardia in the control group was significantly higher
than that of the ephedrine group (14.3% vs. 0%; P<0.05).
There were significant decrease total doses of rescue ephedrine
required in the ephedrine group (P<0.05) (Table 2). Total
doses of used ephedrine in the ephedrine group were signifi-
cant higher than that of control group. The first rescue ephe-
drine time in the ephedrine group was significantly longer
(14.9±7.1 min vs. 7.9±5.4 min) than that of the control
group (P<0.05) (Table 2).
No abnormal CTG tracing was observed until delivery.
Analysis of neonatal data showed no differences between the
study groups. No Apgar scores were below 7 at 1 min or 5
min. Umbilical arterial pH were similar between the study
groups (P>0.05). There was no pH <7.2 in the both groups
(Table 3).
DISCUSSION
This is the first report to our knowledge to investigate the
effect of intravenous ephedrine given according to maternal
weight dose of 0.5 mg/kg after the induction of spinal anes-
thesia for cesarean section to prevent hypotension related to
spinal anesthesia. Our findings demonstrated that prophylac-
tic intravenous ephedrine during spinal anesthesia for cesare-
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Values are number of patients (%) or mea±SD.
*P<0.05 vs. control group.
Ephedrine group Control group
(n=21) (n=21)
Hypotension  8 (38.1%)* 18 (85.7%)
Hypertension 6 (28.6%) 4 (19%)
Tachycardia  11 (52.4%) 6 (28.6%)
Bradycardia 0 (0%)* 3 (14.3%)
Nausea or vomiting  4 (19.0%)* 12 (57.1%)
Rescue ephedrine dose (mg) 4.3±5.9* 18.6±12.7
Total used ephedrine dose (mg) 39.6±8.6* 18.6±12.7
The first rescue ephedrine time (min) 14.9±7.1* 7.9±5.4
Table 2. Hemodynamic data
Values are mean±SD or median (min-max).
Ephedrine group Control group
(n=21) (n=21)
Apgar score 1 min 8 (7-9) 8 (7-9)
Apgar score 5 min 10 (8-10) 10 (8-10)
Umbilical arterial pH 7.34±0.05 7.32±0.03
Table 3. Neonatal data
Fig. 2. Systolic arterial pressure of the ephedrine and control groups.
Values are mean±SD.
*P<0.05 vs. control group; 
� P<0.05 vs. baseline.
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Fig. 3. Heart rate of the ephedrine and control groups.
Values are mean±SD.
*P<0.05 vs. control group.
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Variables Variablesan section can prevent hypotension without significant mater-
nal tachycardia or hypertension, and also it increases the first
rescue ephedrine time and decreases the ratio of nausea and
vomiting. Umbilical arterial pH and Apgar scores were not
influenced by hypotension or ephedrine medication.
The incidence of hypotension during spinal anesthesia for
cesarean section is reported to be as high as 80%, despite fluid
preload, lateral uterine displacement and use of vasopressor
agents (11). In the anesthesia practice, prevention and man-
agement of hypotension related to spinal anesthesia remains
a difficult problem and there was no consensus on its optimal
management. 
Phenylephrine, α 1-adrenergic agonist whose action would
be expected to counteract the decrease in systemic vascular
resistance induced by spinal anesthesia (12). Phenylephrine
can be used for the prevention and treatment of maternal hy-
potension (13-15) but a reduction of fetal oxygenation due
to uterine vasoconstriction has been observed in animals (16).
It may cause maternal bradycardia (14, 17). Loughrey et al.
(18) compared intravenous bolus of ephedrine and phenyle-
phrine combination with ephedrine alone. They found the
combination of ephedrine and phenylephrine given as an in-
travenous bolus was not superior regarding to the incidence
of hypotension, maternal side effects, or umbilical blood gases
when administered as a prophylactic bolus followed by res-
cue boluses and compared to ephedrine alone.
Ephedrine, an indirectly acting sympathomimetic amine,
is probably the vasopressor of choice in obstetric anesthesia.
Although ephedrine has mixed α - and β -adrenoreceptor activ-
ity, it maintains arterial pressure mainly by increases in car-
diac output (CO) and heart rate as a result of its predominant
activity on β 1-adrenoreceptors (19). Variable intravenous infu-
sions of ephedrine appear to be successfu1 (14, 20-22). Kee et
al. (10) investigated the efficacy and optimum dose of intra-
venous ephedrine for prevention of hypotension during spinal
anesthesia for cesarean delivery. They compared the effect of
ephedrine 10, 20, or 30 mg intravenous for the prevention
of hypotension. They found that a bolus dose of 30 mg intra-
venous ephedrine was required to reduce the incidence of hy-
potension during spinal anesthesia for cesarean delivery. They
concluded that although the incidence of hypotension was
reduced to 35% in the patients who received ephedrine 30
mg compared with the control rate of 95%, this was at the
expense of an increased incidence of hypertension, which oc-
curred in 45% of the patients. They suggested that 30-mg
intravenous ephedrine may not be suitable in some patients
such as those with cardiovascular or cerebrovascular disease.
Compared with the study of Kee et al. (10), the incidence of
reactive hypertension is lower in our study (45% vs. 28.6%).
Duration of ephedrine administration in the study of Kee et
al. was 30 sec, however, in our study; it was 60 sec. Decreased
ratio of reactive hypertension in the ephedrine group in our
study may result from the longer duration of ephedrine ad-
ministration. Particularly if sympathetic block level is low,
reactive hypertension may be a problem. In the ephedrine and
control groups, upper sensory level was T4 (T3-T5), howev-
er, it was T4 (C2-T7) in the study of Kee et al. (10), and the
range of sensorial block was wide compared to our study. In-
creased sympathetic activity might be related to compensato-
ry stimulation of thoracic sympathetic nerves, including the
fibers supplying the heart (T1-T4) in the patients undergo-
ing spinal anesthesia (23). Such event also was reported in low
spinal anesthesia and epidural blocks in which sympathetic
block does not reach the T4 level (24). The ratio of reactive
hypertension was similar the patients given intravenous ep-
hedrine and saline (28.6% vs. 19%). In the control group,
cause of reactive hypertension may result from the adminis-
tration of higher doses of rescue ephedrine.
Lee et al. (9) reviewed available studies to determine the
dose-response characteristics of prophylactic intravenous ep-
hedrine for the prevention of hypotension during spinal anes-
thesia for cesarean delivery. They reported that, significant
dose-response relationships were found for hypotension, hy-
pertension and umbilical arterial pH. They suggested that,
the use of larger doses of ephedrine (>14 mg) does not com-
pletely eliminate hypotension but causes reactive hyperten-
sion and a minor decrease in umbilical arterial pH. They fo-
und no evidence of a dose-response relationship for nausea or
vomiting, fetal acidosis, or Apgar scores. Both ratio of hypo-
tension and nausea and vomiting decreased with ephedrine
dose used in this study. 
Some studies found significantly higher umbilical arterial
pH when using prophylactic ephedrine (7). Thus, it seems
that ephedrine must be used during cesarean section to avoid
spinal hypotension, which remains a major determinant of
fetal acidemia (10, 25). Ephedrine has been shown to cross
the placenta and to affect the fetal and neonatal heart rate (26)
due to β -adrenoreceptor activity. A greater proportion of low
umbilical artery pH has been observed with ephedrine than
phenylephrine (12). Previous studies have shown that the use
of ephedrine to prevent or treat hypotension associated with
spinal and epidural anesthesia for cesarean delivery may not
correct fetal acidosis and may even increase it, especially if
hypotension still occurs (5, 22, 27). Kee et al. (10) found that
umbilical blood pH values were lower in patients who had
hypotension compared with patients who did not, whereas
hypertension was not associated with adverse effects. Alth-
ough they did not measure uteroplacental flow, their results
suggest that, within the range of doses used in their study
(10, 20, or 30 mg), the potential vasoconstrictive effects of
ephedrine may have a less detrimental effect on uteroplacen-
tal blood flow than the effects of hypotension. Eisler et al. (28)
demonstrated that fetal catecholamine stimulation before de-
livery might be beneficial. They suggested that when a β -
adrenergic agonist was administered before elective cesarean
section, lower respiratory morbidity, and better lung func-
tion and reduced risk of hypoglycaemia in the newborn infant
were found. In our study, lowest SAP was maintained better
886 I.O. Kol, K. Kaygusuz, S. Gursoy, et al.in patients who received intravenous ephedrine compared
with the control groups. We found no significant difference
in neither Apgar scores nor umbilical arterial blood gases data
between the study groups, despite a difference in the inci-
dence of hypotension, probably reflecting the early recogni-
tion and restoration of hypotension with rescue ephedrine. 
Although mean highest HR in the ephedrine group was
higher, we found no difference in ratio of tachycardia between
the study groups. This could be explained by both the effect
of “rescue” ephedrine and baroreceptor-mediated reflex inc-
reases in heart rate in patients who became hypotensive. In
addition, atropine was applied for bradycardia in the control
group.
These findings suggest, the prophylactic bolus dose of 0.5
mg/kg intravenous ephedrine given at the time of intrathe-
cal block after a crystalloid fluid preload, plus rescue boluses
reduce the incidence of hypotension. It has not been shown
to eliminate the need to treat maternal hypotension during
spinal anesthesia for elective cesarean delivery compared to
intravenous rescue boluses alone.
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